Terazosin Capsule
Product Images NDC 59746-386

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 59746-386). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Fig 1)

Chemical structure of Terazosin Hydrochloride, showing the molecular arrangement including methoxy groups, a piperazine ring, and a carbonyl-linked oxirane group, labeled with Hydrochloride (HCl).*

FDA Label Image

Figure2 (Fig 2)

This chart displays two graphs comparing Terazosin and placebo effects over three months. The left graph shows the mean change in total symptom score from baseline, with Terazosin reducing symptoms more than placebo. The right graph shows the mean increase in peak flow rate, with Terazosin demonstrating a greater increase compared to placebo.*

FDA Label Image

Figure3 (Fig 3)

A line graph showing mean change from baseline over a period of 30 months. The x-axis represents time in months, labeled 0, 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30. The y-axis shows mean change from baseline in values ranging from 0 to -7. Data points are marked with symbols and connected by a line, depicting a trend of decreasing values over time.*

FDA Label Image

Figure4 (Fig 4)

A line graph showing mean change from baseline in mm Hg over 30 months, with data points marked from month 0 to month 30. The graph includes error bars indicating variability, and asterisks denote statistically significant changes at various time points.*

FDA Label Image

1-100s (1 100s)

Label for Terazosin Capsules USP 1 mg by Jubilant Cadista Pharmaceuticals Inc. The label indicates each capsule contains 1 mg Terazosin Hydrochloride equivalent. It states storage instructions, product origin as Germany, package count of 100 capsules, NDC 59746-383-06, and includes standard dispensing and safety instructions.*

FDA Label Image

2-100s (2 100s)

Label for Terazosin Capsules USP 2 mg, oral capsule dosage form. The label includes directions for use and storage, indicates a package count of 100 capsules, and is marketed by Jubilant Cadista Pharmaceuticals Inc. The label also notes the product is made in Germany and advises pharmacists to dispense with a patient information sheet.*

FDA Label Image

5-100s (5 100s)

Label for Terazosin Capsules, USP 5 mg by Jubilant Cadista Pharmaceuticals Inc. The label specifies each capsule contains Terazosin Hydrochloride equivalent to 5 mg Terazosin. It is packaged in a container holding 100 capsules. The label includes storage instructions, dispensing guidance, and identifies the product as made in Germany.*

FDA Label Image

10-100s (10 100s)

Label for Terazosin Capsules, USP 10 mg oral capsules by Jubilant Cadista Pharmaceuticals Inc. The label includes storage instructions (store at 20-25°C), dispensing advice, and packaging details indicating 100 capsules per container. It also states the product is from Germany and provides the NDC 59746-386-06.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.